Sign In
Buy HTBX
$2.38
+0 (+0%)
At Close: Aug 17, 2022
NanOlogy initiates clinical trial in lung cancer utilizing NanoPac based on submicron technology.
Heat Biologics Announces FDA Clearance Of Investigational New Drug Application For PTX-35
11:32am, Monday, 08'th Jun 2020Heat Biologics Announces FDA Clearance of Investigational New Drug (IND) Application for PTX-35
11:30am, Monday, 08'th Jun 2020
DURHAM, NC / ACCESSWIRE / June 8, 2020 / Heat Biologics, Inc. ("Heat") (HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system,
Genprex to Present at the MoneyShow June Virtual Event
12:00am, Monday, 08'th Jun 2020
Genprex's CEO will Present at the MoneyShow Virtual Event on June 10
Mirati Therapeutics to Present at 41st Annual Goldman Sachs Global Healthcare Conference
02:00pm, Friday, 05'th Jun 2020
SAN DIEGO, June 5, 2020 /PRNewswire via COMTEX/ --
SAN DIEGO, June 5, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage...
Regeneron has both added to its current growth drivers and developed an impressive pipeline that should fuel performance throughout the decade. Eylea will benef
Spectrum Pharma nabs Five Prime, Gilead veteran as new clinical lead
11:55am, Thursday, 04'th Jun 2020
After swinging the ax on staffers last year and gaining a new CEO a few months back, Five Prime Therapeutics’ clinical development lead is hoping for a more stable time at new employer Spectrum Phar
Heat Biologics Says On Track To Complete Coronavirus Vaccine Development And Initiate Manufacturing In August
11:38am, Thursday, 04'th Jun 2020Heat Biologics Provides Update on COVID-19 Vaccine Efforts
11:30am, Thursday, 04'th Jun 2020
DURHAM, NC / ACCESSWIRE / June 4, 2020 / Heat Biologics, Inc. ("Heat") (HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system,
Immutep (ASX:IMM) Presentation, Immutep TACTI-002 Clinical Results & Update Global Webcast, February 2020
04:32am, Tuesday, 02'nd Jun 2020
28 Feb 2020 - Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt, Chief Scientific and Medical Officer, Dr Frédéric Triebel, and Director of Clinical Development and Regulatory Affairs,
HTBX: The Antigen Chaperone: gp96
10:15am, Monday, 01'st Jun 2020
By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT Full Year 2019 Results Heat Biologics, Inc. (NASDAQ:HTBX) reported first quarter 2020 results in a May 15th release along with
